Avastin ovarian cancer approval a first for Japan
This article was originally published in Scrip
Executive Summary
Chugai/Roche's Avastin (bevacizumab) has been approved in Japan for the treatment of ovarian cancer, marking the fifth local indication for the product but the first regulatory clearance for an anticancer in the country to be based on an investigator-initiated trial.